Aspirin for primary prevention of coronary events

New England Journal of Medicine

Volumn 346, Issue 19, 2002, Pages 1468-1474

  Lauer, Michael S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CORONARY ARTERY DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SMOKING; STROKE; ALGORITHM; BLOOD; DRUG CONTRAINDICATION; EVIDENCE BASED MEDICINE; HEART INFARCTION; MIDDLE AGED; REVIEW; RISK;

ALGORITHMS; ASPIRIN; CHOLESTEROL; CORONARY DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; RISK;

EID: 0037046655     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp012672     Document Type: Article

References (50)

1. Guide to primary prevention of cardiovascular diseases: A statement for healthcare professionals from the Task Force on Risk Reduction
2. The recent decline in mortality from coronary heart disease, 1980-1990: The effect of secular trends in risk factors and treatment
3. The pathogenesis of coronary artery disease and acute coronary syndromes
4. Inflammation and coronary artery disease
5. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
6. Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood
7. Final report on the aspirin component of the ongoing Physicians' Health Study
8. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis ofrandomised trials
9. Updated guidelines for cholesterol management
10. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation
11. Prediction of coronary heart disease using risk factor categories
12. A case-control study of regular aspirin use and coronary deaths
13. Aspirin and coronary heart disease: Findings of a prospective study
14. Regular aspirin use and myocardial infarction
15. A prospective study of aspirin use and primary prevention of cardiovascular disease in women
16. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis
17. Inhibition of platelet aggregability by moderate-intensity physical exercise: A randomized clinical trial in overweight men
18. Randomised trial of prophylactic daily aspirin in British male doctors
19. Thrombosis Prevention Trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
20. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
21. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice
22. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials
23. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force
24. Aspirin and human platelets: From clinical trials to acetylation of cyclooxygenase and back
25. A metaregression analysis of the dose-response effect of aspirin on stroke
26. Risk of gastrointestinal haemorrhage with long term use of aspirin: A meta-analysis
27. The Women's Health Study: Summary of the study design
28. Determination of who may derive most benefit from aspirin in primary prevention: Subgroup results from a randomised controlled trial
29. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
30. Aspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study report 14
31. Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8
32. Executive summary of the Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
33. Using aspirin and ACE inhibitors in combination: Why the hullabaloo?
34. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: Results of a double-blind, randomized comparative trial
35. Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease
36. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
37. Antiplatelet agents and survival: A cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial
38. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Systematic overview of individual data from 96,712 randomized patients
39. Aspirin and the risk of colorectal cancer in women
40. Aspirin use and risk of fatal cancer
41. Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine
42. Profile and prevalence of aspirin resistance in patients with cardiovascular disease
43. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
44. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
45. The future of antiplatelet therapy: Optimizing management in patients with acute coronary syndrome
46. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale
47. Aspirin as a therapeutic agent in cardiovascular disease: A Statement for Healthcare Professionals from the American Heart Association
48. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
49. British Hypertension Society guidelines for hypertension management 1999: Summary